Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

Published:2020-02 Issue: Volume:301 Page:163-166
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Caocci Giovanni,Mulas Olga,Annunziata Mario,Luciano Luigiana,Abruzzese Elisabetta,Bonifacio Massimiliano,Orlandi Ester Maria,Albano Francesco,Galimberti Sara,Iurlo Alessandra,Pregno Patrizia,Sgherza Nicola,Martino Bruno,Binotto Gianni,Castagnetti Fausto,Gozzini Antonella,Bocchia Monica,Fozza Claudio,Stagno Fabio,Simula Maria Pina,De Gregorio Fiorenza,Trawinska Malgorzata Monika,Scaffidi Luigi,Elena Chiara,Attolico Imma,Baratè Claudia,Cattaneo Daniele,Pirillo Francesca,Gugliotta Gabriele,Sicuranza Anna,Molica Matteo,La Nasa Giorgio,Foà Robin,Breccia Massimo

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference13 articles.

1. European society of cardiology: cardiovascular disease statistics 2017;Timmis;Eur. Heart J.,2018

2. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol Off J Am Soc Clin Oncol,2016

3. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol,2015

4. Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-medicare data;Lang;Clin. Lymphoma, Myeloma & Leukemia,2016

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study;Annals of Hematology;2024-06-11

2. CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter Study;2024-03-13

3. A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia;Pharmaceutics;2024-03-11

4. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management;Journal of Clinical Medicine;2024-03-09

5. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12